MiRagen Therapeutics has named Aimee Jackson as its director of target development and Christopher Morl as its chief business officer.
Jackson previously served as director of drug discovery at microRNA drug firm Regulus Therapeutics. Before that, she was a senior research fellow at Rosetta Inpharmactics, a former Merck subsidiary.
Morl most recently was a pharmaceutical industry consultant, and has held various roles at Ambit Biosciences, Agensys, and GlaxoSmithKline.
Regulus Therapeutics has appointed Stelios Papadopoulos as the chairman of its board.
Papadopoulos assumed the position from Alnylam Pharmaceuticals CEO John Maraganore, who will remain a Regulus board member.
A member of Regulus’ board since 2008, Papadopoulos is on the boards of several companies including Biogen Idec and is chairman of Exelixis.
RNAi researcher and ETH Zurich professor Olivier Voinnet has received the Rossler Prize.
As part of the prize, Voinnet was awarded CHF200,000 ($215,586), which he said he will invest in his ongoing research into the antiviral roles of RNAi in mammalian cells.
The prize was established by mathematician Max Rossler in 2007 to honor promising ETH Zurich researchers.